Pfizer (NYSE:PFE) issued an update on its FY21 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $3.00-3.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.97. Pfizer also updated its FY 2021
After-Hours guidance to 3.00-3.10 EPS.
PFE opened at $36.86 on Thursday. The company has a quick ratio of 1.16, a current ratio of 1.42 and a debt-to-equity ratio of 0.78. Pfizer has a 52 week low of $27.88 and a 52 week high of $43.08. The business’s 50 day moving average is $38.25 and its two-hundred day moving average is $37.19. The firm has a market cap of $204.88 billion, a price-to-earnings ratio of 14.63, a price-to-earnings-growth ratio of 3.10 and a beta of 0.66.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.01. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The business had revenue of $12.13 billion for the quarter, compared to analyst estimates of $12.30 billion. During the same period last year, the firm posted $0.75 earnings per share. The company’s revenue for the quarter was down 4.3% compared to the same quarter last year. Equities analysts expect that Pfizer will post 2.84 EPS for the current fiscal year.
A number of equities analysts recently issued reports on the company. Zacks Investment Research raised Pfizer from a sell rating to a hold rating and set a $37.00 price target on the stock in a report on Thursday, October 29th. BidaskClub downgraded Pfizer from a sell rating to a strong sell rating in a research note on Thursday, December 31st. Barclays upped their price target on Pfizer from $35.00 to $37.00 and gave the stock an equal weight rating in a research note on Friday, December 4th. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research report on Tuesday, November 10th. They issued a market perform rating and a $42.00 price objective on the stock. Finally, SVB Leerink upped their price objective on shares of Pfizer from $42.00 to $43.00 and gave the stock a market perform rating in a research report on Wednesday, October 28th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of $39.87.
In other news, major shareholder Pfizer Inc acquired 1,200,000 shares of Pfizer stock in a transaction that occurred on Tuesday, October 27th. The stock was purchased at an average cost of $10.00 per share, with a total value of $12,000,000.00. Following the completion of the acquisition, the insider now owns 27,349,211 shares in the company, valued at approximately $273,492,110. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.08% of the company’s stock.
Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.
Featured Story: Backdoor Roth IRA Conversion and Strategy
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.